Cochlear Limited (ASX: COH) share price jumps on broker upgrade

medical advancement, Hearing aids, medical technology

The Cochlear Limited (ASX: COH) share price is booking in its third day of gains as the stock bounces from Monday’s more than one-year low of $156.03.

The COH share price jumped 2.7% to $167.04 in early trade when the S&P/ASX 200 (Index:^AXJO) (ASX: XJO) index is up 0.4%.

Cochlear is leading the healthcare sector higher and is beating its peers including the RESMED/IDR UNRESTR (ASX: RMD) share price, CSL Limited (ASX: CSL) share price and Nanosonics Ltd. (ASX: NAN) share price.

Strong soundings

The hearing implant company is getting a boost from a broker upgrade with Morgan Stanley upping its recommendation on Cochlear to “overweight” from “equal-weight” as it looked it the impact of the acquisition of Sycle.

The broker believes the takeover of Sycle will significantly increase the adoption rate of Cochlear Implants (CI). Sycle is an audiology practice management software used by around 7,000 hearing aid clinics in the US, UK and Canada.

“We estimate current developed market penetration [for CI] at ~5% and capture of annual incidence of severe/profound hearing impairment at only ~7%,” said Morgan Stanley.

“Low penetration is explained by weak relationships between hearing aid and CI audiology channels. Sycle will bridge this channel divide and sustain long-term CI market growth.”

Valuation upside

The broker estimates that around 100,000 patients a year progress to severe/profound hearing loss that are also customers at Sycle hearing aid clinics but are not referred on to a CI clinic.

This missed opportunity is due to low CI awareness among hearing aid clinics and the Sycle acquisition will give Cochlear a chance to market their solutions to this channel and to turn some of the hearing aid clinics into CI service centres.

Every 5,000 increase in patients adopting CIs will add $15 to the broker’s price target on Cochlear of $175 per share.

The stock’s close to 30% drop since September also means the stock is trading around 4% above the 10-year average forward price-earnings (P/E) multiple relative to the ASX 200 (excluding financials).

But Cochlear isn’t the only blue-chip stock that looks well placed to outperform. The experts at the Motley Fool are also tipping three other hot stocks to own for 2019.

Follow the free link below to find out what these are and why they should be on your radar.

Top 3 ASX Blue Chips To Buy For 2019

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2019."

Each one pays a fully franked dividend. The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Brendon Lau owns shares of CSL Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.